6-BIBLIOGRAFIA
Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845–867
Beigel A, Murphy DL, Bunney WE: The Maniac-State Rating Scale. Scale construction, reliability, and validity. Arch Gen Psychiatry 1971; 25:256
Bonk T, Humeny A: MALDI-TOF-MS Analysis of Protein and DNA.The Neuroscientist 2001; 1 (7): 6-12
Brunner J, Bronisch T, Uhr M, Ising M, Binder E, Holsboer F, Turck CW:
Proteomic analysis of the CSF in unmedicated patients with major depressive disorder reveals alterations in suicide attempters. Eur Arch Psychiatry Clin Neurosci. 2005 Dec;255(6):438-40
Chan KC, Lucas DA, Hise D, Schaefer CF, Xiao Z, Janini GM: Analysis of the human serum proteome. Clin Proteomics 2004; 1: 101–226
Choudhary J, Grant SGN: Proteomics in postgenomic neuroscience: the end of the beginning. Nature Neuroscience 2004; 5 (7): 440-445
Coelho FM, Reis HJ, Nicolato R, Romano-Silva MA, Teixeira MM, Bauer ME, Teixeira AL: Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia. Neuroimmunomodulation 2008;
15:140-4
Craddock RM, Huang JT, Jackson E, Harris N, Torrey EF, Herberth M, Bahn S:
Increased alpha-defensins as a blood marker for schizophrenia susceptibili. Mol Cell Proteomics 2008, 7(7):1204-13
Dietrich-Muszalska A, Olas B: The changes of aggregability of blood platelets in schizophrenia. World J Biol Psychiatry 2007;14 :1-6
Dietrich-Muszalska A, Olas B, Rabe-Jablonska J: Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005; 16:386-91
Domenici E, Willé DR, Tozzi F, Prokopenko I, Miller S, McKeown A, Brittain C, Rujescu D, Giegling I, Turck CW, Holsboer F, Bullmore ET, Middleton L, Merlo-Pich E, Alexander RC, Muglia P: Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 2010; Feb 11;5(2):e9166
English JA, Pennington K, Dunn MJ, Cotter DR: The neuroproteomics of schizophrenia. Biol Psychiatry 2011;15;69(2):163-72
Fagiolini A, Dell'Osso L, Pini S, Armani A, Bouanani S, Rucci P, Cassano GB, Endicott J, Maser J, Shear MK, Grochocinski VJ, Frank E:
Validity and reliability of a new instrument for assessing mood symptomatology: the Structured Clinical Interview for Mood Spectrum (SCI- MOODS)
Int J Meth Psych Res 1999;8:71-81
First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P) New York: Biometrics Research, New York State Psychiatric Institute, November 2002
Fischer BA, Carpenter WT Jr: Will the Kraepelinian dichotomy survive DSM- V? Neuropsychopharmacology 2009; Aug;34(9):2081-7
Giusti L, Baldini C, Bazzichi L, Ciregia F, Tonazzini I, Mascia G, Giannaccini G, Bombardieri S, Lucacchini A: Proteome analysis of whole saliva: a new tool for rheumatic diseases--the example of Sjögren's syndrome. Proteomics, 2007;
7(10):1634-1643
Godovac-Zimmermann J, Soskic V, Poznanovic S, Brianza F: Functional proteomics of signal transduction by membrane receptors, Electrophoresis 1999;
20 (4-5): 952-961
Gygi SP, Han DK, Gingras AC, Sonenberg N, Aebersold R. Protein analysis by mass spectrometry and sequence database searching: tools for cancer research in the post-genomic era. Electrophoresis 1999; 20: 310–319
Hamilton M: The assessment of anxiety states by rating. Brit J Med Psychol 1959; 32:50.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiat 1960;
23:56
Herbert BR, Harry JL, Packer NH, Gooley AA, Pedersen SK, Williams KL:
What place for polyacrylamide in proteomics? Trends Biotechnol. 2001 Oct;19(10 Suppl):S3-9
Herberth M, Koethe D, Levin Y, Schwartz E, Krzyszton ND, Schoeffmann S, Ruh H, Rahmoune H, Kranaster L, Schoenborn T, Lewekw MF, Guest PC, Bahn S: Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival. Proteomics 2011 Jan; 11(1):94-105
Huang JT, Leweke FM, Tsang TM, Koethe D, Kranaster L, Gerth CW, Gross S, Schreiber D, Ruhrmann S, Schultze-Lutter F, Klosterkotter J, Holmes E, Bahn S: CSF Metabolic and Proteomic Profiles in Patients Prodromal for Psychosis.
PLoS ONE 2007; 22;2(1):e756
Husi H, Grant SGN: Proteomics of the nervous system. Trends in Neurosciences 2001; 5 (24): 259-266
Imam-Sghiouar N, Laude-Lemaire I, Labas V, Pflieger D, Le Caer JP, Caron M, Nabias DK, Joubert-Caron R: Subproteomics analysis of phosphorylated proteins: application to the study of B-lymphoblast from a patient with Scott syndrome”. Proteomics 2002; 2 (7): 828-838
Jimenez CR, Li KW, Dreisewerd K, Spijker S, Kingston R, Bateman RH, Burligame AL, Smit AB, ven Minnen J, Geraerst WP: Direct mass spectrometric peptide profiling and sequencing of single neurons reveals differential peptide patterns in a small neuronal network Biochemistry 1998; 37: 2070-2076
Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:26
Kraepelin E. Lehrbuch der Psychiatrie. Leipzig: Barth, 1896.
Langen H, Berndt P, Roder D, Cairns N, Lubec G, Fountoulakis M: Two- dimensional map of human brain proteins. Electrophoresis 1999; 20: 907-916
Levin Y, Wang L, Schwarz E, Koethe D, Leweke FM, Bahn S: Global proteomic profiling reveals altered proteomic signature in schizophrenia serum.
Molecular Psychiatry 2010 Nov;15(11):1088-100. Epub 2009 Jun 23
Maj M: Is it possible to explain complex mental disorders at the biological level? World Psychiatry 2011;10:1
Martins-de-Souza D, Dias-Neto E, Schmitt A, Falkai P, Gormanns P, Maccarrone G, Turck CW, Gattaz WF: Proteome analysis of schizophrenia brain tissue. World J Biol Psychiatry 2010 Mar;11(2):110-20
Mc Gorry PD, Gleeson JFM: Psychological Interventions in Early Psychosis: A Treatment Handbook. 2004
Novikova SI, He F, Cutrufello NJ, Lidow MS: Identification of protein
biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI- TOF-PSD-MS analysis. Neurobiol Dis. 2006 Jul;23(1):61-76. Epub 2006 Mar 20
Owen MJ: Is there a schizophrenia to diagnose? World Psychiatry 2011;10:34- 35
Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000;
405: 837-846
Phizicky E, Bastiaens PI, Zhu H, Snyder M, Fields S: Protein analysis on a proteomic scale. Nature 2003; 422: 208-215
Porton B, Delisi LE, Bertisch HC, Ji F, Gordon D, Li P, Benedict MM,Greenberg WM, Kao HT: Telomerase levels in schizophrenia: A preliminary study. Schizophr Res 2008, 106:242-7
Sbrana A, Dell’Osso L, Benvenuti A, Rucci P, Cassano P, Banti S, Gonnelli C,
Frank E, Kupfer DJ, Cassano GB. The psychotic spectrum: validity and reliability of the Structured Clinical Interview for the Psychotic Spectrum.
Schizophrenia Research 2005;75:375– 387
Schwarz E, Bahn S: The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders. British Journal of Pharmacology 2008; 153:133–136
Van Os J, Kapur S: Schizophrenia. Lancet 2009; Aug 22;374(9690):635-45
Wang L, Lockstone HE, Guest PC, Levin Y, Palota A, Pietsch S, Schwarz E, Wilkins MR, Williams KL, Appeal RD, Hochstrasser DF:Proteome research:
new frontiers in functional genomics. Springer Verlag, Berlin, Heidelberg 1997;
1-12
